By Fineline Cube Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that China’s National Medical Products Administration (NMPA) has granted approval to initiate a Phase I clinical study evaluating HLX48, a bispecific antibody-drug conjugate (ADC) targeting c-MET and EGFR, in patients with metastatic, advanced solid tumors.
Regulatory & Development Status
| Item | Detail |
|---|---|
| Regulatory Agency | National Medical Products Administration (NMPA), China |
| Trial Phase | Phase I (first-in-human) |
| Indication | Metastatic, advanced solid tumors |
| Molecule Type | Bispecific antibody-drug conjugate (ADC) |
| Targets | c-MET and EGFR (dual-targeting) |
| Development Status | Independently developed by Henlius Biotech |
Drug Mechanism & Multi-Modal Action
- Targeted Delivery: HLX48 specifically binds to c-MET/EGFR-positive tumor cells, inducing receptor-mediated internalization and subsequent release of cytotoxic payload within tumor cells
- Direct Cytotoxicity: Released toxin molecules cause DNA damage and tumor cell death through direct mechanism
- Bystander Effect: Toxin demonstrates bystander killing activity, eliminating adjacent tumor cells regardless of target expression status
- Signaling Inhibition: Antibody variable region blocks ligand binding of epidermal growth factor (EGF) and hepatocyte growth factor (HGF) to their respective receptors, inhibiting downstream signaling pathway activation
- Immune Engagement: Crystallizable fragment (Fc) region mediates antibody-dependent cell-mediated cytotoxicity (ADCC), engaging immune effector cells against tumor targets
Strategic Significance & Market Context
- Innovation Milestone: HLX48 represents Henlius’ advancement into complex bispecific ADC technology, combining the precision of dual-targeting antibodies with the potency of cytotoxic payloads
- Therapeutic Rationale: Simultaneous targeting of c-MET and EGFR addresses key resistance mechanisms in solid tumors, as these pathways are frequently co-activated or compensatory in treatment-resistant cancers
- Competitive Differentiation: The triple-mechanism approach (direct cytotoxicity + signaling inhibition + ADCC) distinguishes HLX48 from conventional ADCs and single-target bispecific antibodies
- Platform Validation: Successful development would validate Henlius’ integrated bispecific ADC platform, enabling rapid pipeline expansion across multiple tumor types
- Market Opportunity: Advanced solid tumors with c-MET/EGFR co-expression represent a significant unmet medical need, particularly in gastrointestinal, lung, and head/neck cancers where both pathways drive progression
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical trial initiation, regulatory approvals, and development expectations for HLX48. Actual results may differ due to risks including trial outcomes, safety findings, and competitive dynamics.-Fineline Info & Tech